We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+8.97%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$425M
AUM Growth
-$23.3M
Cap. Flow
+$875K
Cap. Flow %
0.21%
Top 10 Hldgs %
49.03%
Holding
60
New
17
Increased
11
Reduced
11
Closed
10

Top Buys

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$8.7M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$6.55M
3
GYRE icon
Gyre Therapeutics
GYRE
+$6.09M
4
CLDX icon
Celldex Therapeutics
CLDX
+$5.74M
5
VRDN icon
Viridian Therapeutics
VRDN
+$5.62M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$12.9M
2
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$10.6M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$9.61M
4
SURF
Surface Oncology, Inc. Common Stock
SURF
+$9.24M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$8.51M

Sector Composition

Rank Sector Weight
1 Healthcare 82.31%
2 Miscellaneous 17.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$488B
$47.9M 11.25%
150,000
+50,000
+50% +$16M
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$1.85B
$26.3M 6.18%
1,175,000
-175,000
-13% -$3.95M
TRIL
3
DELISTED
Trillium Therapeutics Inc.
TRIL
$20.9M 4.92%
1,950,000
– –
ARKG icon
4
PUT
ARK Genomic Revolution ETF
ARKG
$2B
$17.7M 4.17%
+200,000
New +$19.8M
ASND icon
5
Ascendis Pharma A/S
ASND
$17.8B
$17.4M 4.09%
135,000
+30,000
+29% +$4.56M
KURA icon
6
Kura Oncology
KURA
$1.17B
$17M 3.99%
600,000
+275,000
+85% +$8.7M
IOVA icon
7
Iovance Biotherapeutics
IOVA
$3.94B
$15.8M 3.72%
500,000
– –
FATE icon
8
Fate Therapeutics
FATE
$290M
$15.3M 3.58%
185,000
+20,000
+12% +$1.92M
XENE icon
9
Xenon Pharmaceuticals
XENE
$5.85B
$15.2M 3.58%
850,000
+150,000
+21% +$2.54M
ACRS icon
10
Aclaris Therapeutics
ACRS
$876M
$15.1M 3.55%
600,000
-50,000
-8% -$978K
RCKT icon
11
Rocket Pharmaceuticals
RCKT
$416M
$14.4M 3.39%
325,000
-175,000
-35% -$9.61M
COGT icon
12
Cogent Biosciences
COGT
$6.06B
$14M 3.3%
1,600,000
+500,000
+45% +$4.81M
ARVN icon
13
Arvinas
ARVN
$609M
$13.6M 3.18%
205,000
– –
APLS
14
DELISTED
Apellis Pharmaceuticals
APLS
$9.65M 2.27%
225,000
-100,000
-31% -$4.73M
TGTX icon
15
TG Therapeutics
TGTX
$8.68B
$9.64M 2.27%
200,000
-50,000
-20% -$2.4M
VTGN icon
16
VistaGen Therapeutics
VTGN
$10.9M
$8.83M 2.07%
138,123
+56,790
+70% +$3.79M
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.56M 2.01%
50,000
– –
VRNA
18
DELISTED
Verona Pharma
VRNA
$7.85M 1.85%
939,043
+129,043
+16% +$1.07M
ALDX icon
19
Aldeyra Therapeutics
ALDX
$89.3M
$7.72M 1.81%
650,000
– –
MRSN
20
DELISTED
Mersana Therapeutics
MRSN
$7.28M 1.71%
18,000
-6,000
-25% -$2.91M
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$6.95M 1.63%
1,125,000
-250,000
-18% -$1.52M
IWM icon
22
iShares Russell 2000 ETF
IWM
$81B
$6.63M 1.56%
+30,000
New +$6.55M
CNST
23
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$6.43M 1.51%
275,000
-350,000
-56% -$10.6M
BIIB icon
24
Biogen
BIIB
$33.2B
$5.59M 1.32%
20,000
+17,800
+809% +$4.8M
CLDX icon
25
Celldex Therapeutics
CLDX
$3.09B
$5.15M 1.21%
+250,000
New +$5.74M
1
2 3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Ghost Tree Capital held 60 positions worth $425M, down 5.2% from $449M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Ghost Tree Capital's Q1 2021 filing shows 17 new, 11 increased, 11 reduced and 10 closed positions. Its largest new stake was iShares Russell 2000 ETF: 30,000 shares worth $6.63M. The largest sale was Travere Therapeutics, an estimated $12.9M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 90% a quarter earlier, followed by Miscellaneous.

  • Ghost Tree Capital's largest Q1 2021 buy was iShares Russell 2000 ETF: 30,000 shares worth $6.63M.
  • Ghost Tree Capital added most to Kura Oncology in Q1 2021, an estimated $8.7M increase.
  • Ghost Tree Capital's biggest Q1 2021 reduction was Constellation Pharmaceuticals, Inc., cutting an estimated $10.6M.
  • Ghost Tree Capital fully exited Travere Therapeutics in Q1 2021, selling an estimated $12.9M.
  • Ghost Tree Capital's ten largest holdings make up 49% of its $425M portfolio in Q1 2021.
  • Ghost Tree Capital opened 17 new positions and closed 10 in Q1 2021.
  • Ghost Tree Capital's portfolio value fell 5.2% quarter-over-quarter to $425M.

Based on Ghost Tree Capital's 13F filing for Q1 2021, filed 14 May 2021.